Chronic osteomyelitis
Chronic osteomyelitis caused by Staphylococcus aureus (including MRSA) is notoriously difficult to cure because the organism forms biofilms on devitalized bone and orthopedic hardware, hides intracellularly, and switches to dormant small-colony variants that tolerate even prolonged antibiotic courses, leaving debridement plus weeks-to-months of antibiotics with high relapse rates. Bacteriophages are a compelling adjunct here: they are self-amplifying lytic agents that penetrate and disrupt biofilm extracellular matrix, kill metabolically quiescent cells that beta-lactams and vancomycin miss, and can be delivered locally into bone and joint spaces at the site of infection. Because phages are strain-specific, they spare the surrounding microbiota and can be matched to a patient's isolate via susceptibility testing (phagogram). The strongest rationale is for hardware-associated and difficult-to-treat, antibiotic-refractory S. aureus bone infection where surgical and antibiotic options have been exhausted.
How phages act here
Mechanism
Lytic Staphylococcus phages (largely Herelleviridae/Twort-like myoviruses such as those in commercial anti-S. aureus cocktails) adsorb to wall teichoic acid and peptidoglycan receptors, inject their genome, replicate, and lyse the cell, then amplify on remaining bacteria so dose rises where bacterial burden is highest. Critically for osteomyelitis, phages and their depolymerase/endolysin enzymes degrade the biofilm matrix on bone and implants, exposing sequestered and small-colony-variant cells that tolerate conventional antibiotics. Strain specificity is leveraged through phagogram-guided selection and multi-phage cocktails that broaden host range and raise the genetic barrier to phage resistance. Phage-antibiotic synergy is a central theme: sub-lethal antibiotics can enhance phage replication and, conversely, phage selection pressure can resensitize S. aureus to antibiotics, so phages are used as an adjunct to (not a replacement for) surgical debridement plus antibiotics. Engineering and CRISPR/endolysin (lysin) approaches are advancing preclinically to improve biofilm penetration and counter resistance, though clinical bone-infection use so far relies on natural lytic phages.
Where it stands
Current evidence
As of 2026 the evidence base is early-phase but accelerating, spanning compassionate-use case series and the first randomized trials. The landmark controlled study is PhagoDAIRI (NCT05369104, sponsor Phagenix), a randomized double-blind Phase 2 pilot of two GMP anti-S. aureus phages (PP1493 and PP1815) given after debridement-antibiotics-implant-retention (DAIR) for hip/knee prosthetic joint infection; reported outcomes describe roughly 80% infection control at 3 months in the phage-treated pilot cohort. In an adjacent bone indication, BiomX reported positive topline Phase 2 results (March 2025, DANCE trial) for its fixed phage cocktail BX211 in S. aureus diabetic foot osteomyelitis, with a statistically significant, sustained reduction in ulcer area versus placebo on a background of standard antibiotics (41 patients, IV plus topical phage). Real-world programs such as PHAGEinLYON at Hospices Civils de Lyon have delivered GMP phage cocktails (intravenous and local injection) for complex S. aureus bone and joint infections under compassionate access, with most treated patients showing favorable clinical evolution. Earlier compassionate-use experience also includes the Australian AB-SA01 anti-S. aureus cocktail. Animal and ex vivo work (e.g., a 2025 MRSA fracture-related-infection sheep model) confirms safety as an antibiotic adjunct but flags rapid phage clearance and neutralizing-antibody development as dosing/delivery challenges still being optimized.
Evidence confidence: medium
The data
Key studies & trials
- PhagoDAIRI. Phage Therapy in Prosthetic Joint Infection Due to Staphylococcus aureus Treated With DAIR (Phase 2 randomized, double-blind pilot; phages PP1493 and PP1815; sponsor Phagenix). ClinicalTrials.gov identifier NCT05369104. ↗
- Peng J, Guo C, Yang C, et al. Phage therapy for bone and joint infections: A comprehensive exploration of challenges, dynamics, and therapeutic prospects. Journal of Global Antimicrobial Resistance. 2024;39:12-21. ↗
- Ferry T, Le Bouar M, Briot T, et al. Access to phage therapy at Hospices Civils de Lyon in 2022: Implementation of the PHAGEinLYON Clinic programme. International Journal of Antimicrobial Agents. 2024;64(6):107372. ↗
- Plumet L, Ahmad-Mansour N, Dunyach-Remy C, et al. Bacteriophage Therapy for Staphylococcus aureus Infections: A Review of Animal Models, Treatments, and Clinical Trials. Frontiers in Cellular and Infection Microbiology. 2022;12:907314. ↗
Who is working on it
Programs & centers
The possibility
If current Phase 2 signals hold, phage cocktails could become a standard adjunct at the operating table — surgeons debriding infected hardware may one day irrigate the bone bed with a patient-matched phage mixture, or implant phage-eluting cement and coatings that keep killing biofilm bacteria for weeks after closure. Pairing rapid phagogram matching with engineered, longer-circulating or endolysin-armed phages could finally crack the small-colony-variant and biofilm reservoirs that drive relapse, turning many "incurable," hardware-retaining chronic osteomyelitis cases into salvageable limbs. The biggest near-term win is resensitization: using phages to herd S. aureus back into antibiotic susceptibility, shrinking the months-long antibiotic courses that define this disease today.